			PATENT COOPE	RATION TRE	ATY	REC'D 17 00	T 2005
rom the NTERNATIO	ONAL SEARCI	HING AUTH	ORITY			WIPO	
NTERNATIONAL SEARCHING AUTHORITY To: CATHERINE M. POLIZZI MORRISON & FOERSTER LLP 755 PAGE MILL ROAD PALO ALTO, CA 94304				PC	$\overline{\mathbf{CT}}$	PCT	
			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY				
				·	(PCT Rul	e 43 <i>bis</i> .1)	
				Date of mailing (day/month/year)		13 OCT 2	.005
Applicant's or agent's file reference				FOR FURTHER ACTION See paragraph 2 below			
5595920002 Internationa	241 Il application No	··	International filing date	(day/month/year)	Priority date	(day/month/year)	
PCT/US04/	41081		08 December 2004 (08.	12.2004)	08 December	r 2003 (08.12.2003)	
		cation (IPC)	or both national classificat				
IPC(7): CO	7D 471/04; A 6	1 K 31/437 a	and US Cl.: 546/81; 514/2	292		•	
Applicant							
MEDIVAT	ION, INC.				·		
1. This op	oinion contains i	ndications rel	ating to the following iten	ns:			
Box No. I Basis of the opinion			٠				
Box No. II Priority					•		
	Box No. III	Non-establ	ishment of opinion with re	egard to novelty, inve	ntive step and i	ndustrial applicability	,
\boxtimes	Box No. IV	Lack of uni	ity of invention			•	
\boxtimes	Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
	Box No. VI Certain documents cited						
	Box No. VII Certain defects in the international application						
	Box No. VIII Certain observations on the international application						
2 FID2T	HER ACTIO	N					,
If a de Interna Author	mand for intern tional Prelimina ity other than th	ational prelin ary Examinir ais one to be	ninary examination is mang Authority ("IPEA") ethe IPEA and the chosen	xcept that this does IPEA has notified the	not apply whose International	here the applicant cl	hooses an

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

			j '
Name and mailing address of the ISA/ US	Date of completion of this opinion	Authorized officer	11
Mail Stop PCT, Attn: ISA/US Commissioner for Patents	19 September 2005 (19.09.2005)	Rita J. Desai Valurus Bell	-Harre
P.O. Box 1450	19 September 2003 (19.09.2003)		
Alexandria, Virginia 22313-1450	1	Telephone Nc. (57/)272-/600	
Pacsimile No. (703) 305-3230	<u> </u>	13.7	j
Form PCT/ISA/237 (cover sheet) (April 2005)			

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/41081

Box No. I Basis of this opinion									
1. With regard to the language, this opinion has been established on the basis of:									
\boxtimes	the international application in the language in which it was filed								
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).								
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:									
a.	type of material								
•	a sequence listing								
	table(s) related to the sequence listing								
ъ.	format of material								
	on paper								
	in electronic form								
c.	time of filing/furnishing								
	contained in the international application as filed.								
	filed together with the international application in electronic form.								
	furnished subsequently to this Authority for the purposes of search.								
3. 🗌	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.								
4. Additi	nal comments:								
,									

Form PCT/ISA/237(Box No. I) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/41081

Box No. IV Lack of unity of invention									
1. In response to the invitation (Form PCT/ISA/206) to pay additional fees the applicant has, within the applicable time limit: paid additional fees paid additional fees under protest and, where applicable, the protest fee paid additional fees under protest but the applicable protest fee was not paid not paid additional fees not paid additional fees This Authority found that the requirement of unity of invention is not complied with and chose not to invite the applicant to									
pay additional fees. This Authority considers that the requirement of unity of invention in accordance with Rule 13.1, 13.2 and 13.3 is									
complied with introduced not complied with for the following reasons: See the lack of unity section of the International Search Report(Form PCT/ISA/210)									
4. Consequently, this opinion has been established in respect of the following parts of the international application: all parts. the parts relating to claims Nos. 1-76 and 95-132									

Form PCT/ISA/237 (Box No. IV) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/41081

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
1. Statement		•				
Novelty (N)	Claims 4-18, 22-36, 40-54, 59-94, 116-132	YES				
	Claims 1-3, 19-21, 37-39, 55-58, 95-97, 113-115	NO				
Inventive step (IS)	Claims 4-18, 22-36, 40-54, 59-94, 116-132	YES				
	Claims 1-3, 19-21, 37-39, 55-58, 95-97, 113-115	NO				
Industrial applicability (IA)	Claims 1-76, 95-132	YES				
Aldudain approach, (act,	Claims NONE	NO				
		<u> </u>				

2. Citations and explanations:

Claim1-3, 19-21, 37-39, 55-58, 95-97, 113-115 lack novelty under PCT Article 33(2) as being anticipated by US 5563147 Gilmore et al, see the hydrogenated pyrido (4,3b) indole compounds and also line 41 column 6 of the reference. Claims 4-18, 22-36, 40-54, 59-94, 116-132 meet the criteria set out in PCT Article 33(4), and thus meet industrial applicability because the subject matter claimed can be made or used in industry.

Form PCT/ISA/237 (Box No. V) (April 2005)